Literature DB >> 21531040

The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study.

David Fiorentino1, Lorinda Chung, Jeff Zwerner, Antony Rosen, Livia Casciola-Rosen.   

Abstract

BACKGROUND: Dermatomyositis (DM) is a multisystem autoimmune disease, in which serologic evidence of immune responses to disease-specific antigenic targets is found in approximately 50% to 70% of patients. Recently, melanoma differentiation-associated gene 5 (MDA5) has been identified as a DM-specific autoantigen that appears to be targeted in patients with DM and mild or absent muscle inflammation and with an increased risk of interstitial lung disease.
OBJECTIVE: We wished to understand the role of MDA5 in DM skin inflammation by testing it to determine if a specific cutaneous phenotype is associated with MDA5 reactivity.
METHODS: We retrospectively screened plasma from 77 patients with DM in the outpatient clinics at the Stanford University Department of Dermatology in California.
RESULTS: We found that 10 (13%) patients had circulating anti-MDA5 antibodies, and had a characteristic cutaneous phenotype consisting of skin ulceration, tender palmar papules, or both. Typical areas of skin ulceration included the lateral nailfolds, Gottron papules, and elbows. Biopsy specimens of the palmar papules showed a vasculopathy characterized by vascular fibrin deposition with variable perivascular inflammation. Patients with anti-MDA5 antibodies also had an increased risk of oral pain and/or ulceration, hand swelling, arthritis/arthralgia, and diffuse hair loss. Consistent with previous reports, these patients had little or no myositis and had increased risk of interstitial lung disease. LIMITATIONS: This study was conducted at a tertiary referral center. Multiple associations with MDA5 antibodies were tested retrospectively on a relatively small cohort of 10 anti-MDA5-positive patients.
CONCLUSION: We suggest that MDA5 reactivity in DM characterizes a patient population with severe vasculopathy.
Copyright © 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21531040      PMCID: PMC3167687          DOI: 10.1016/j.jaad.2010.09.016

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  41 in total

1.  Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations.

Authors:  Pamela A Morganroth; Mary Elizabeth Kreider; Joyce Okawa; Lynne Taylor; Victoria P Werth
Journal:  Arch Dermatol       Date:  2010-07

2.  Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.

Authors:  Kei Hoshino; Yoshinao Muro; Kazumitsu Sugiura; Yasushi Tomita; Ran Nakashima; Tsuneyo Mimori
Journal:  Rheumatology (Oxford)       Date:  2010-05-25       Impact factor: 7.580

3.  Keratotic palmar papules in a dermatomyositis patient preceding the development of interstitial pneumonia.

Authors:  Yoshinori Sasaki; Ryuhei Okuyama; Takahiko Tsunoda; Hachiro Tagami; Setsuya Aiba
Journal:  Dermatology       Date:  2007       Impact factor: 5.366

Review 4.  Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate immunity.

Authors:  Paola M Barral; Devanand Sarkar; Zao-zhong Su; Glen N Barber; Rob DeSalle; Vincent R Racaniello; Paul B Fisher
Journal:  Pharmacol Ther       Date:  2009-07-15       Impact factor: 12.310

5.  RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease.

Authors:  Shinji Sato; Kana Hoshino; Takashi Satoh; Tomonobu Fujita; Yutaka Kawakami; Takashi Fujita; Masataka Kuwana
Journal:  Arthritis Rheum       Date:  2009-07

6.  Interferon-induced helicase (IFIH1) polymorphism with systemic lupus erythematosus and dermatomyositis/polymyositis.

Authors:  Takahisa Gono; Yasushi Kawaguchi; Tomoko Sugiura; Takefumi Furuya; Manabu Kawamoto; Masanori Hanaoka; Hisashi Yamanaka
Journal:  Mod Rheumatol       Date:  2010-05-14       Impact factor: 3.023

7.  Dermatomyositis with multiple skin ulcers showing vasculitis and membrano-cystic lesion.

Authors:  T Yamamoto; H Ohkubo; I Katayama; K Nishioka
Journal:  J Dermatol       Date:  1994-09       Impact factor: 4.005

8.  The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody.

Authors:  Ran Nakashima; Yoshitaka Imura; Shio Kobayashi; Naoichiro Yukawa; Hajime Yoshifuji; Takaki Nojima; Daisuke Kawabata; Koichiro Ohmura; Takashi Usui; Takao Fujii; Katsuya Okawa; Tsuneyo Mimori
Journal:  Rheumatology (Oxford)       Date:  2009-12-16       Impact factor: 7.580

9.  The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis.

Authors:  Cynthia M Magro; Jeremy P Segal; A Neil Crowson; Paul Chadwick
Journal:  J Cutan Pathol       Date:  2009-11-04       Impact factor: 1.587

Review 10.  Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression.

Authors:  Harsha Gunawardena; Zoe E Betteridge; Neil J McHugh
Journal:  Rheumatology (Oxford)       Date:  2009-06       Impact factor: 7.580

View more
  138 in total

1.  Anti-MDA5-Positive Dermatomyositis Presenting as Fever of Unknown Origin.

Authors:  Lori W Lee; Neera S Narang; Anna Postolova; Nicole Seminara; Molly A Kantor
Journal:  J Gen Intern Med       Date:  2016-12       Impact factor: 5.128

Review 2.  [Dermatomyositis-specific antibodies].

Authors:  L Bodoki; M Nagy-Vincze; Z Griger; K Dankó
Journal:  Z Rheumatol       Date:  2015-05       Impact factor: 1.372

Review 3.  Classification of myositis.

Authors:  Ingrid E Lundberg; Marianne de Visser; Victoria P Werth
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

4.  Inverse Gottron papules in juvenile dermatomyositis: an under recognized clinical entity.

Authors:  Ankur Kumar Jindal; Sandesh Guleria; Rakesh Kumar Pilania; Anuradha Bishnoi; Keshavamurthy Vinay; Sunil Dogra; Deepti Suri; Amit Rawat; Surjit Singh
Journal:  Rheumatol Int       Date:  2018-05-02       Impact factor: 2.631

Review 5.  The evolving spectrum of polymyositis and dermatomyositis--moving towards clinicoserological syndromes: a critical review.

Authors:  Sarah Tansley; Harsha Gunawardena
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

6.  Distinct dermatomyositis populations are detected with different autoantibody assay platforms.

Authors:  David F Fiorentino; Laura Gutierrez-Alamillo; David Hines; Qingyuan Yang; Livia Casciola-Rosen
Journal:  Clin Exp Rheumatol       Date:  2019-07-19       Impact factor: 4.473

Review 7.  Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.

Authors:  Kun Huang; Ophir Vinik; Kam Shojania; James Yeung; Rachel Shupak; Michael Nimmo; J Antonio Avina-Zubieta
Journal:  Rheumatol Int       Date:  2019-08-02       Impact factor: 2.631

8.  Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis.

Authors:  Yoshinao Muro; Kazumitsu Sugiura; Masashi Akiyama
Journal:  Clin Rheumatol       Date:  2012-12-19       Impact factor: 2.980

9.  Identification of novel autoantigens by a triangulation approach.

Authors:  Tricia R Cottrell; John C Hall; Antony Rosen; Livia Casciola-Rosen
Journal:  J Immunol Methods       Date:  2012-08-11       Impact factor: 2.303

Review 10.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.